Finvest
IDYA Biotechnology · Clinical stage · Oncology · Precision medicine · Thesis updated July 1, 2026

Darovasertib now carries the IDYA story

01 Running thesis

Lead drug moves closer

IDEAYA is still a high-risk biotech, but the story changed in 2026. In April 2026, the company said OptimUM-02, the key darovasertib trial, hit both progression-free survival and an overall survival rate endpoint with statistical significance. Progression-free survival means patients lived longer before the cancer got worse.

The next big step is regulatory. IDEAYA plans to submit a New Drug Application, or NDA, in the second half of 2026 for darovasertib plus crizotinib in first-line metastatic uveal melanoma. The FDA also agreed to review the filing under Real-Time Oncology Review, a program meant to speed review of strong cancer data.

The bull case is simple: darovasertib may become IDEAYA's first approved drug, and the company had $972.9 million in cash, cash equivalents, and marketable securities at March 31, 2026. That gives it time to file the NDA and keep funding other cancer programs.

The bear case has not gone away. IDEAYA has never launched a drug. The FDA could ask for more data, delay the review, or reject the filing. There is also a data nuance to watch: the Q1 2026 filing says the overall survival rate improved with statistical significance, while the ASCO 2026 update described median overall survival as not yet mature. Mature survival data still matter.

May 2026▲IDEAYA reported positive topline PFS and overall survival rate data from OptimUM-02 and said it plans an NDA submission in the second half of 2026. Cash and marketable securities were $972.9 million.
Feb 2026→The 2025 10-K showed $1.05 billion in cash and marketable securities and laid out four pipeline focus areas. It also confirmed GSK would terminate the collaboration covering IDE705 and IDE275.
Nov 2025▲Servier licensed darovasertib rights outside the United States, paying $210.0 million upfront with up to $320.0 million in potential milestones. The deal strengthened the balance sheet and added outside validation for the lead asset.
Aug 2025→IDEAYA reported $991.9 million in cash and marketable securities and $122.8 million of operating cash use for the first half of 2025. The update sharpened focus on upcoming clinical readouts and cash burn.
May 2025▲The FDA granted Breakthrough Therapy Designation for darovasertib in neoadjuvant uveal melanoma, and IDEAYA received U.S. IND clearance for IDE849. The pipeline gained momentum while research spending rose.
Feb 2025▲The 2024 10-K showed a larger pipeline, including the in-licensed IDE849 DLL3 ADC and new development candidates. The broader pipeline added more shots on goal but also raised future spending needs.
Nov 2024→The initial thesis framed IDEAYA as a clinical-stage precision oncology company with no product revenue, a strong cash position, and trial risk centered on its cancer pipeline.
Aug 2024→The 10-Q amendment did not include substantive financial, operating, or risk updates. No thesis change was made.
02 Business model

Paid by partners, not patients

IDEAYA does not sell medicine yet. Its revenue has come from collaboration deals, mainly GSK historically and Servier after the August 2025 ex-U.S. darovasertib license. These deals can include upfront cash, milestone payments, and royalties if drugs reach the market.

The Servier deal gave IDEAYA $210.0 million upfront and potential future milestones of up to $320.0 million, plus double-digit royalties on net sales outside the United States. IDEAYA kept the U.S. opportunity for darovasertib, which could matter if the drug is approved.

The model breaks if trials fail, regulators say no, or launch costs outrun the balance sheet. IDEAYA is also carrying a wide pipeline, so research spending can rise as more programs enter later and larger trials.

03 Product portfolio

Four shots, one lead asset

Growth engine

Darovasertib for uveal melanoma

This is IDEAYA's most advanced program. It is being tested in metastatic, neoadjuvant, and adjuvant uveal melanoma, a rare eye cancer often linked to GNAQ and GNA11 mutations.

Option

IDE849, DLL3 antibody drug conjugate

IDE849 is aimed at DLL3-positive solid tumors, including small cell lung cancer and neuroendocrine tumors. IDEAYA plans a clinical data update in the second half of 2026.

Option

IDE161, PARG inhibitor

IDE161 is part of the DNA damage response strategy. The idea is to attack cancers that depend on certain repair pathways to survive.

Option

IDE397, MAT2A inhibitor

IDE397 targets tumors with MTAP deletion. This is a selected cancer group, which fits IDEAYA's plan to match drugs to tumor biology.

Option

IDE892, PRMT5 inhibitor

IDE892 is another MTAP-pathway program. It is designed as an MTA-cooperative PRMT5 inhibitor for solid tumors with MTAP gene deletion.

Option

IDE034 and IDE574

IDE034 is a B7H3/PTK7 bispecific antibody drug conjugate, and IDE574 is a KAT6/7 dual inhibitor. Both add future upside, but they are less proven than darovasertib.

04 Business segments

One research business

Targeted oncology research and development100%growing fast
Commercial product sales0%flat

IDEAYA reports as one operating segment focused on targeted cancer drug discovery and development. For Q1 2026, the company had no commercial products, so product sales were 0% and revenue exposure was tied to collaborations.

05 Risk factors

What could break

FDA says the package is not enough

High impact · Medium odds

Darovasertib is much less risky after positive OptimUM-02 topline data, but it is not approved. The FDA could still ask for longer follow-up, a different endpoint analysis, or more safety data. That would push out the first possible product revenue.

We watchNDA submission timing in the second half of 2026 and any FDA filing acceptance or complete response letter.

Survival data disappoint

High impact · Medium odds

The Q1 2026 filing says the trial showed a statistically significant improvement in overall survival rate. The later ASCO 2026 release said median overall survival was not yet mature. If the mature survival curve weakens, investor trust in the launch opportunity could fall.

We watchUpdated overall survival data from OptimUM-02, including hazard ratio, p-value, and median overall survival.

First launch is harder than expected

High impact · Medium odds

IDEAYA has no prior commercial launch record. Even a good rare cancer drug needs doctors to test the right patients, payers to cover it, and a sales team that can reach specialist centers. The U.S. launch build could also raise spending before revenue arrives.

We watchHiring for commercial roles, launch spending, payer coverage signals, and the first reported U.S. sales if approved.

Cash burn rises with the pipeline

Medium impact · High odds

The company had $972.9 million in cash and marketable securities at March 31, 2026, which is a strong position for a clinical-stage biotech. Still, later-stage trials cost more, and IDEAYA is advancing multiple programs at once. A faster burn rate could lead to future stock sales.

We watchQuarterly operating cash use, research and development expense, and any new equity financing.

Supply chain or policy shock

Medium impact · Medium odds

The company has flagged new U.S. policy risks. The BIOSECURE Act could limit use of certain foreign contract manufacturers, and Medicaid funding cuts from the One Big Beautiful Bill Act could hurt future sales if an approved drug depends on that payer base.

We watchManufacturing partner changes, disclosed CMO exposure, Medicaid coverage policy, and any supply delays.
06 Quick answers

In one breath

Does IDEAYA Biosciences have any approved drugs?

No. IDEAYA has no approved products and no product sales. Its most advanced drug is darovasertib, which the company plans to submit to the FDA in the second half of 2026.

What is darovasertib used for?

Darovasertib is being developed for uveal melanoma, a rare cancer that starts in the eye and can spread to the liver and other organs. The lead setting is first-line metastatic uveal melanoma in HLA-A2 negative patients.

How does IDEAYA make money today?

IDEAYA makes money from collaboration and license agreements, not drug sales. The Servier deal for darovasertib outside the United States included a $210.0 million upfront payment.

What is the main thing to watch next?

The key watch item is the darovasertib NDA submission in the second half of 2026. Investors should also watch updated overall survival data and how quickly IDEAYA builds a U.S. launch team.